Funding Clinical Trials

Funding Clinical Trials

Our Agency funds clinical trials testing promising stem cell-based treatments for currently incurable diseases or disorders to help patients with unmet medical needs. For basic information about stem cell trials, visit our Clinical Trials 101 page. For a list of clinical trials that are a result of early-stage CIRM grants click here.

CIRM Clinical Dashboard

Disease Areas Investigator Organizationsort descending Phase Trial Status Targeted Enrollment Detail
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 42
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Active, not recruiting 10
David Williams Boston Children's Hospital Phase 2 Recruiting 15
Krystof Bankiewicz Brain Neurotherapy Bio Phase 1 Recruiting 12
Ralph Kern BrainStorm Cell Therapeutics Phase 3 Completed 263
William Sietsema Caladrius Biosciences Phase 2 Completed 113
Robert Dillman Caladrius Biosciences Phase 3 Closed 4
Kristen Johnson Calibr Phase 1 Completed 60
Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 13
Rachel Smith Capricor, Inc Phase 2 Closed 156
Linda Marban Capricor, Inc Phase 2 Completed 25
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
  • Pulmonary Hypertension
 Michael Lewis Cedars-Sinai Medical Center Phase 1/2 Recruiting 26
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Launching N/A
Clive Svendsen Cedars-Sinai Medical Center Phase 1/2 Completed 18
  • COVID-19
 Xiaokui Zhang Celularity Inc Phase 1/2 Active, not recruiting 86
Michael Pulsipher Children's Hospital of Los Angeles Phase 1/2 Active, not recruiting 60
Joseph Rosenthal City of Hope, Beckman Research Institute Phase 1 Recruiting 6
John Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
Saul Priceman City of Hope, Beckman Research Institute Phase 1 Recruiting 39
  • COVID-19
 John Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
Leo Wang City of Hope, Beckman Research Institute Phase 1 Recruiting 18
Christine Brown City of Hope, Beckman Research Institute Phase 1 Recruiting 92
Pierre Caudrelier ExCellThera Inc. Phase 1 Recruiting 12
Mark Chao Forty Seven Inc. Phase 1/2 Completed 78
  • Leukemia, Acute Myeloid (AML)
 Mark Chao Forty Seven Inc. Phase 1 Recruiting 287
Jane Lebkowski Geron Corporation Phase 1 Completed 5
Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 355
Jeffrey Lawson Humacyte, Inc. Phase 3 Recruiting 240
  • Leukemia, Acute Myeloid (AML)
 Joseph Woodard Immune-Onc Therapeutics Phase 1 Recruiting 44
Anthony Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 414
Henry Klassen jCyte, Inc Phase 2 Completed 84
Henry Klassen jCyte, Inc Phase 2 Completed 84
Francois Binette Lineage Cell Therapeutics Inc. Phase 1/2 Completed 25
Daniel Brennan Medeor Therapeutics, Inc. Phase 3 Active, not recruiting 30
  • Leukemia, Acute Myeloid (AML)
 Colleen Delaney Nohla Therapeutics Inc Phase 2 Closed 146
  • Multiple Myeloma
 Matthew Spear Poseida Therapeutics, Inc. Phase 1 Active, not recruiting 220
  • Leukocyte Adhesion Deficiency
 Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Active, not recruiting 9
Gayatri Rao Rocket Pharmaceuticals, Inc. Phase 1 Active, not recruiting 2
Bijan Nejadnik SanBio, Inc. Phase 2 Completed 163
  • Beta Thalassemia
 Bettina Cockroft Sangamo BioSciences, Inc. Phase 1/2 Active, not recruiting 6
Stephen Gottschalk St. Jude Children's Research Hospital Phase 1/2 Recruiting 28
David Miklos Stanford University Phase 1 Recruiting 57
Everett Meyer Stanford University Phase 1 Recruiting 22
Judith Shizuru Stanford University Phase 1/2 Recruiting 40
Irving Weissman Stanford University Phase 1 Completed 88
Samuel Strober Stanford University Phase 1 Active, not recruiting 15
Gary Steinberg Stanford University Phase 1 Recruiting 30
Crystal Mackall Stanford University Phase 1 Recruiting 54
  • B cell cancers
  • Leukemia
  • Leukemia, Acute Myeloid (AML)
 Maria Grazia Roncarolo Stanford University Phase 1 Launching N/A
Mehrdad Abedi University of California, Davis Phase 1/2 Recruiting 18
Nancy Lane University of California, Davis Phase 1/2 Completed 58
  • Spina Bifida
 Diana Farmer University of California, Davis Phase 1 Recruiting 55
Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
Henry Klassen University of California, Irvine Phase 1/2 Completed 28
  • X-linked Chronic Granulomatous Disease
 Donald Kohn University of California, Los Angeles Phase 1/2 Recruiting 16
Donald Kohn University of California, Los Angeles Phase 1 Recruiting 6
Steven Dubinett University of California, Los Angeles Phase 1 Recruiting 24
Donald Kohn University of California, Los Angeles Phase 2 Completed 10
  • Sarcoma
 Theodore Nowicki University of California, Los Angeles Phase 1 Recruiting 12
  • Corneal Damage
 Sophie Deng University of California, Los Angeles Phase 1 Recruiting 20
Dennis Slamon University of California, Los Angeles Phase 1 Active, not recruiting 48
Antoni Ribas University of California, Los Angeles Phase 1 Recruiting 12
Stephanie Cherqui University of California, San Diego Phase 1/2 Recruiting 6
Thomas Kipps University of California, San Diego Phase 1 Completed 26
Thomas Kipps University of California, San Diego Phase 1/2 Recruiting 160
  • Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
 Morton Cowan University of California, San Francisco Phase 1 Recruiting 25
  • Alpha Thalassemia Major
 Tippi MacKenzie University of California, San Francisco Phase 1 Recruiting 10
Peter Stock University of California, San Francisco Phase 1/2 Recruiting 8
  • COVID-19
 Michael Matthay University of California, San Francisco Phase 2 Recruiting 120
Steven Deeks University of California, San Francisco Phase 1/2 Launching N/A
Mark Walters University of California, San Francisco Phase 1 Launching N/A
Mark Humayun University of Southern California Phase 1 Active, not recruiting 16
Howard Foyt ViaCyte, Inc. Phase 1/2 Closed 19
Howard Foyt ViaCyte, Inc. Phase 1/2 Recruiting 75
Icon for XLSX export